Hypothyroidism associated with therapy for multi-drug-resistant tuberculosis in Australia.
Yee-Ming Melody CheungKaren VanLan LanRahul D BarmanraySarah Y QianWilliam Y ShiJennifer L A WongPeter S HamblinPeter G ColmanDuncan J ToplissJustin T DenholmMathis GrossmannPublished in: Internal medicine journal (2019)
Prothionamide/PAS treatment-associated hypothyroidism is common in MDR-TB patients in Australia, emphasising the importance of regular thyroid function monitoring during this treatment. Thyroid hormone replacement, if initiated, may not need to be continued after MDR-TB treatment is completed.